INSERM – National Institute of Health and Medical Research
INSERM has a long standing experience in the regulation of tolerability and efficacy of cancer treatments by the circadian timing system, ranging from rodents to patients. It has conceived and implemented chronomodulated treatment delivery to take advantage of the control mechanisms through which the circadian clock modulates normal tissue physiology and tumour growth. The present research work focuses on the control of normal and malignant cellular proliferation by the circadian clock as a determinant of cancer treatment success. We further address the relevance of circadian clock mechanisms in the efficiency of compensatory cell proliferation.